Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Open-label, Multi-center, Dose-escalation Study to Evaluate Safety, Pharmacokinetics and Activity of CH5132799 Administered Orally as a Monotherapy in Patients With Advanced Solid Tumors

NCT01222546 is registered in ClinicalTrials.gov with Chugai Pharma Europe Ltd. as lead sponsor.

NCT NCT01222546
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01222546 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Open-label, Multi-center, Dose-escalation Study to Evaluate Safety, Pharmacokinetics and Activity of CH5132799 Administered Orally as a Monotherapy in Patients With Advanced Solid Tumors
Lead sponsor
Chugai Pharma Europe Ltd.
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2010
Completion date
December 31, 2012
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors